Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Wei Z. Ai, MD
Published: Wednesday, Aug 08, 2018



Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.


Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x